Nigerian Medical Journal

CASE REPORT
Year
: 2015  |  Volume : 56  |  Issue : 1  |  Page : 74--76

Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm


Abdulaziz Hassan, Livingstone Gayus Dogara, Ahmadu Aliyu Babadoko, Sani Awwalu, Aisha Indo Mamman 
 Department of Haematology, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria

Correspondence Address:
Abdulaziz Hassan
Department of Haematology, Ahmadu Bello University Teaching Hospital, PMB 06 Shika, Zaria 810001, Kaduna State
Nigeria

The World Health Organisation (WHO) classifies myeloproliferative neoplasm (MPN) into BCR-ABL positive chronic myeloid leukaemia (CML Ph + ) and Ph MPN. The JAK2 V617F mutation is specific for Ph MPN and occurs in approximately 50% of primary myelofibrosis. Earlier reports suggest that the occurrence of JAK2 and BCR-ABL mutations are mutually exclusive. However, recent reports have documented the coexistence of BCR-ABL and JAK2 mutation in the same patient mostly following treatment with tyrosine kinase inhibitors (TKIs). We thus report a 60-year-old male with atypical clinical and laboratory features of MPN and the presence of both BCR-ABL and JAK2 Mutations.


How to cite this article:
Hassan A, Dogara LG, Babadoko AA, Awwalu S, Mamman AI. Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm.Niger Med J 2015;56:74-76


How to cite this URL:
Hassan A, Dogara LG, Babadoko AA, Awwalu S, Mamman AI. Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm. Niger Med J [serial online] 2015 [cited 2024 Mar 29 ];56:74-76
Available from: https://www.nigeriamedj.com/article.asp?issn=0300-1652;year=2015;volume=56;issue=1;spage=74;epage=76;aulast=Hassan;type=0